Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
European Journal of Clinical Microbiology & Infectious Diseases
Published in: European Journal of Clinical Microbiology & Infectious Diseases 2/2006

01-02-2006 | Brief Report

Observational study of respiratory syncytial virus-associated hospitalizations and use of palivizumab in premature infants aged 29–32 weeks

Authors: B. Resch, W. Gusenleitner, W. D. Müller, J. Haas

Published in: European Journal of Clinical Microbiology & Infectious Diseases | Issue 2/2006

Login to get access

Excerpt

The national observational multicenter cohort study presented here was conducted over two respiratory syncytial virus (RSV) seasons (2001–2003) in Austria to collect data on RSV-related rehospitalizations in premature infants of 29–32-weeks’ gestational age. The results revealed an overall RSV hospitalization rate of 4.5% (36/801). Risk factors were discharge from the neonatal intensive care unit between the months of October and December, birth between June and December 2002, and neurological disease. Palivizumab prophylaxis was given to 238 (29.7%) infants, and 148 infants received inadequate or incomplete courses. …
Literature
1.
McCormick MC, Shapiro S, Starfield BH (1980) Rehospitalization in the first year of life for high-risk survivors. Paediatrics 66:991–999
2.
American Academy of Paediatrics (1998) Prevention of respiratory syncytial virus infections: indications for use of palivizumab and update on the use of RSV–IGIV. Paediatrics 102:1211-1216CrossRef
3.
Zaknun D, Resch B, Jürgenssen O, et al (2001) Prevention of respiratory syncytial virus (RSV) infection in preterm infants with palivizumab (Synagis). Monatsschr Kinderheilkd 149:176–178
4.
Resch B, Gusenleitner W, Mandl C, Müller W (2000) Epidemiology of respiratory syncytial virus infection in southern Austria. Pediatr Infect Dis J 9:587–588CrossRef
5.
Groothuis JR, Simoes EAF, Levin MJ, and the RSVIG Study Group (1993) Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. N Engl J Med 329:1524–1530CrossRefPubMed
6.
Liese JG, Grill E, Fischer B, Roeckl-Wiedmann I, Carr D, Belohradsky BH, for the Munich RSV Study Group (2003) Incidence and risk factors of respiratory syncytial virus-related hospitalizations in premature infants in Germany. Eur J Pediatr 162:230–236PubMed
7.
Simoes EAF, Groothuis JR (2002) Respiratory syncytial virus prophylaxis the story so far. Respir Med 96 (Suppl B):15-24
8.
Arnold SR, Wang EEL, Law BJ, Boucher FD, Stephens D, Robinson JL, Dobson S, Langley JM, McDonald J, MacDonald NE, Mitchell I (1999) Variable morbidity of respiratory syncytial virus infection in patients with underlying lung disease: a review of the PICNIC RSV database. Pediatr Infect Dis J 18:866–869CrossRefPubMed
9.
Parnes C, Guillermin J, Habersang R, et al (2003) Palivizumab prophylaxis of respiratory syncytial virus disease in 2000–2001: results from the palivizumab outcome registry. Pediatr Pulmonol 35:484-489CrossRefPubMed
10.
Sáez-Llorens X, Castaño E, Null D, et al (1998) Safety and pharmacokinetics of an intramuscular humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia: the MEDI-493 Study Group. Pediatr Infect Dis J 17:787–791CrossRefPubMed
Metadata
Title
Observational study of respiratory syncytial virus-associated hospitalizations and use of palivizumab in premature infants aged 29–32 weeks
Authors
B. Resch
W. Gusenleitner
W. D. Müller
J. Haas
Publication date
01-02-2006
Publisher
Springer-Verlag
Published in
European Journal of Clinical Microbiology & Infectious Diseases / Issue 2/2006
Print ISSN: 0934-9723
Electronic ISSN: 1435-4373
DOI
https://doi.org/10.1007/s10096-005-0082-y

Other articles of this Issue 2/2006

European Journal of Clinical Microbiology & Infectious Diseases 2/2006 Go to the issue

Announcements

Announcements

Concise Article

Serotype distribution and antimicrobial resistance of Salmonella enterica from patients with gastroenteritis in Crete, Greece

Brief Report

Etiologic diagnosis of Capnocytophaga canimorsus meningitis by broad-range PCR

Brief Report

CTX-M-3 extended-spectrum beta-lactamase-producing Klebsiella pneumoniae and dissemination of the plasmidic bla CTX-M-3 in Bulgaria

Article

Dexamethasone treatment in adults with pneumococcal meningitis: risk factors for death

Article

Relationship between hepatitis C virus (HCV) and insulin resistance, endothelial perturbation, and platelet activation in HIV–HCV–coinfected patients under highly active antiretroviral treatment
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits